Stallergenes Selects Magic Software's iBOLT to Optimize Communication between its Core Business Systems
Poster: SySAdmin
Posted on January 17, 2012 at 3:07:01 AM
Stallergenes Selects Magic Software's iBOLT to Optimize Communication between its Core Business Systems
French Biopharmaceutical Company will use iBOLT to Streamline Integration between its Purchasing and SAP Systems
OR YEHUDA, Israel, January 17, 2012/PRNewswire-FirstCall/ --
Magic Software Enterprises Ltd. [http://www.magicsoftware.com ] (NASDAQ: MGIC
[http://www.nasdaq.com/symbol/mgic ]), a global provider of mobile
[http://www.magicsoftware.com/en/solutions/?catID13 ] and cloud-enabled application
[http://www.magicsoftware.com/en/products/?catIDp ] and business integration
[http://www.magicsoftware.com/en/products/?catIDA ] platforms, announced today that
Stallergenes [http://www.stallergenes.com/en ], a biopharmaceutical company and world
leader in the treatment of severe allergic respiratory illnesses, has chosen Magic
Software's iBOLT integration platform [http://www.magicsoftware.com/en/products/?catIDA
] to integrate its various purchasing systems with its SAP ERP
[http://www.sap.com/index.epx ].
In 2005, Stallergenes used iBOLT to build an online prescription tracking service that
streamlined its back-office information flows. Following this successful implementation,
Stallergenes has now launched a new project, once again using Magic's technology, to
optimize communication between its purchasing and ERP systems
[http://www.magicsoftware.com/en/products/?catIDA ]. iBOLT linked Stallergenes' disparate
systems, enabling them to automatically convert purchase orders and entries from its
Lawson M3 ERP, hosted on an AS/400 server (IBM System i
[http://www.magicsoftware.com/en/products/?catIDA&pageIDh ]), before integrating them
into the company's SAP Financials management system
[http://www.magicsoftware.com/en/products/?catIDA&pageIDb ].
"iBOLT serves as the communication hub for our various applications. It is our
'orchestra conductor', communicating natively with our various systems," comments Thierry
Grehaigne, CIO of Stallergenes. "It has enabled us to optimize our workflows, making them
reliable and completely transparent for users, whether they are at our French, German, or
Italian site."
"For more than five years now, iBOLT
[http://www.magicsoftware.com/en/products/?catIDA ] has enabled us to implement a
high-performance, paperless infrastructure," he adds. "Because it has always been able to
safeguard existing systems, we can look ahead to future technological changes with
confidence."
"We are very pleased that Stallergenes has once again chosen Magic Software's
products," said Guy Bernstein, CEO of Magic Software. "Magic Software's iBOLT business
integration platform [http://www.magicsoftware.com/en/products/?catIDA ] has again
proven its ease-of-use and ability to deliver rapid time-to-market integration solutions."
About Magic Software
Magic Software Enterprises Ltd. (NASDAQ: MGIC) is a global provider of mobile and
cloud-enabled application and business integration platforms.
For more information, visit http://www.magicsoftware.com.
About Stallergenes
Stallergenes is a European biopharmaceutical company that focuses on allergenic
immunotherapy to treat allergic respiratory illnesses, such as rhinoconjunctivitis, severe
rhinitis, and allergic asthma.
A pioneer and leader in sublingual immunotherapy, Stallergenes ploughs more than 20%
of its revenue back into R&D, and seeks to develop a new therapeutic classification:
sublingual immunotherapy tablets.
In 2010, over 500,000 patients were treated with Stallergenes products.
For more information, visit http://www.stallergenes.com
[http://www.stallergenes.com/en ].
Except for the historical information contained herein, the matters discussed in this
news release include forward-looking statements that may involve a number of risks and
uncertainties. Actual results may vary significantly based upon a number of factors
including, but not limited to, risks in product and technology development, market
acceptance of new products and continuing product conditions, both here and abroad,
release and sales of new products by strategic resellers and customers, and other risk
factors detailed in the Company's most recent annual report and other filings with the
Securities and Exchange Commission.
Press Contact:
Tania Amar, VP Global Marketing
Magic Software Enterprises
Tel: +972-(0)3-538-9300
tania@magicsoftware.com
Source: Magic Software Enterprises Ltd
French Biopharmaceutical Company will use iBOLT to Streamline Integration between its Purchasing and SAP Systems
OR YEHUDA, Israel, January 17, 2012/PRNewswire-FirstCall/ --
Magic Software Enterprises Ltd. [http://www.magicsoftware.com ] (NASDAQ: MGIC
[http://www.nasdaq.com/symbol/mgic ]), a global provider of mobile
[http://www.magicsoftware.com/en/solutions/?catID13 ] and cloud-enabled application
[http://www.magicsoftware.com/en/products/?catIDp ] and business integration
[http://www.magicsoftware.com/en/products/?catIDA ] platforms, announced today that
Stallergenes [http://www.stallergenes.com/en ], a biopharmaceutical company and world
leader in the treatment of severe allergic respiratory illnesses, has chosen Magic
Software's iBOLT integration platform [http://www.magicsoftware.com/en/products/?catIDA
] to integrate its various purchasing systems with its SAP ERP
[http://www.sap.com/index.epx ].
In 2005, Stallergenes used iBOLT to build an online prescription tracking service that
streamlined its back-office information flows. Following this successful implementation,
Stallergenes has now launched a new project, once again using Magic's technology, to
optimize communication between its purchasing and ERP systems
[http://www.magicsoftware.com/en/products/?catIDA ]. iBOLT linked Stallergenes' disparate
systems, enabling them to automatically convert purchase orders and entries from its
Lawson M3 ERP, hosted on an AS/400 server (IBM System i
[http://www.magicsoftware.com/en/products/?catIDA&pageIDh ]), before integrating them
into the company's SAP Financials management system
[http://www.magicsoftware.com/en/products/?catIDA&pageIDb ].
"iBOLT serves as the communication hub for our various applications. It is our
'orchestra conductor', communicating natively with our various systems," comments Thierry
Grehaigne, CIO of Stallergenes. "It has enabled us to optimize our workflows, making them
reliable and completely transparent for users, whether they are at our French, German, or
Italian site."
"For more than five years now, iBOLT
[http://www.magicsoftware.com/en/products/?catIDA ] has enabled us to implement a
high-performance, paperless infrastructure," he adds. "Because it has always been able to
safeguard existing systems, we can look ahead to future technological changes with
confidence."
"We are very pleased that Stallergenes has once again chosen Magic Software's
products," said Guy Bernstein, CEO of Magic Software. "Magic Software's iBOLT business
integration platform [http://www.magicsoftware.com/en/products/?catIDA ] has again
proven its ease-of-use and ability to deliver rapid time-to-market integration solutions."
About Magic Software
Magic Software Enterprises Ltd. (NASDAQ: MGIC) is a global provider of mobile and
cloud-enabled application and business integration platforms.
For more information, visit http://www.magicsoftware.com.
About Stallergenes
Stallergenes is a European biopharmaceutical company that focuses on allergenic
immunotherapy to treat allergic respiratory illnesses, such as rhinoconjunctivitis, severe
rhinitis, and allergic asthma.
A pioneer and leader in sublingual immunotherapy, Stallergenes ploughs more than 20%
of its revenue back into R&D, and seeks to develop a new therapeutic classification:
sublingual immunotherapy tablets.
In 2010, over 500,000 patients were treated with Stallergenes products.
For more information, visit http://www.stallergenes.com
[http://www.stallergenes.com/en ].
Except for the historical information contained herein, the matters discussed in this
news release include forward-looking statements that may involve a number of risks and
uncertainties. Actual results may vary significantly based upon a number of factors
including, but not limited to, risks in product and technology development, market
acceptance of new products and continuing product conditions, both here and abroad,
release and sales of new products by strategic resellers and customers, and other risk
factors detailed in the Company's most recent annual report and other filings with the
Securities and Exchange Commission.
Press Contact:
Tania Amar, VP Global Marketing
Magic Software Enterprises
Tel: +972-(0)3-538-9300
tania@magicsoftware.com
Source: Magic Software Enterprises Ltd